Rachel E. Lerner - Concepedia

Author

Rachel E. Lerner

Clark University ORCID

Also Known As

Lerner, Rachel, R E Lerner, R Lerner, R. E. Lerner, Rachel E Lerner, Rachel E. Lerner, Rachel Lerner, Young-Dae Kim

Publications

926

Citations

H-Index

Concepts

All Affiliations

Clark University Frauenshuh Cancer Center Florida Cancer Specialists & Research Institute European Institute of Oncology University of Minnesota

About

Rachel E. Lerner is an author at Clark University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	560
2	Education	4	4	214
3	Health Sciences	1	1	19
4	Public Health	1	1	19
5	Social Sciences	1	1	117

Rachel E. Lerner

Publications

868

Citations

H-Index

Page 1

	Year	Citations
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial Joel W. Neal, Suzanne E. Dahlberg, Heather A. Wakelee, The Lancet Oncology MedicineCancer ManagementMetronomic TherapyPathologyEcog-acrin 1512	2016	133
Effectiveness of a Brief Preventive Parenting Intervention Based in Self-Determination Theory Wendy S. Grolnick, Madeline R. Levitt, Alessandra Caruso, Journal of Child and Family Studies Family MedicineFamily InvolvementParentingSelf-determination TheoryIntervention Mechanism	2021	121
Maternal involvement and children’s academic motivation and achievement: The roles of maternal autonomy support and children’s affect Rachel E. Lerner, Wendy S. Grolnick Motivation and Emotion Student MotivationChild Well-beingSocioemotional DevelopmentBehavioral SciencesFamily Involvement	2019	117
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, Journal of Clinical Oncology	2024	91
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial Ignace Vergote, Giovanni Scambia, David M. O’Malley, The Lancet Oncology Advanced Ovarian CancerMedicinePharmacologyGynecologyFirst-line Treatment	2019	85
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, Annals of Oncology Nivolumab Versus DocetaxelMedicinePharmacologyAnti-cancer AgentPhase Iii Study	2023	78
Parental involvement and children’s academics: The roles of autonomy support and parents’ motivation for involvement Rachel E. Lerner, Wendy S. Grolnick, Alessandra Caruso, Contemporary Educational Psychology Family InvolvementFamily InteractionEducational PsychologyS AcademicsTeacher-student Relation	2021	62
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in Second Complete or Partial Remission Rachel E. Lerner, William Thomas, Todd E. DeFor, Biology of Blood and Marrow Transplantation Following Auto HsctImmunologyPathologyAutologous TransplantationImmunotherapy	2007	51
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) Alice Shapiro, Susan Adlis, Kim Robien, Breast Cancer Research and Treatment Bone DiseaseRheumatologyVitamin D3MedicineChronic Musculoskeletal Condition	2016	44
Construction of an overproduction vector containing the novel <i>srp</i> (sterically repressed) promoter Khosro Ezaz‐Nikpay, Ken Uchino, Rachel E. Lerner, Protein Science	1994	19

Page 1